Modelling the long-term benefits of photodynamic therapy (PDT) with Verteporfin for age-related macular degeneration (AMD)

David Smith, Mike Drummond () and Paul Fenn
Additional contact information
Mike Drummond: Centre for Health Economics, The University of York

No 187chedp, Working Papers from Centre for Health Economics, University of York

Abstract: Age related macular degeneration (AMD) is the leading cause of blindness in the United Kingdom and the rest of the western world. It occurs in 15% to 30% of individuals over 75 years of age. About 15% of these patients develop a more aggressive wet form of the disease that causes severe loss of vision. This report contains estimates of the benefits of photodynamic therapy (PDT) with verteporfin therapy using a modeling approach based on clinical trial data. While this report covers only the effects of the treatment, the model built was customizable so that it could be populated with local cost data. This made it possible to use the model to help inform local formulary decisions.

Keywords: clinical trial; blindness; vision (search for similar items in EconPapers)
Pages: 18 pages
Date: 2002-03
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://www.york.ac.uk/media/che/documents/papers/d ... on%20Paper%20187.pdf First version, 2003 (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:chy:respap:187chedp

Access Statistics for this paper

More papers in Working Papers from Centre for Health Economics, University of York Contact information at EDIRC.
Bibliographic data for series maintained by Gill Forder ().